ArticleWorld journal of surgical oncology2012
High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.
Article in World journal of surgical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- A meta-analysis of CXCL12 expression for cancer prognosis.British journal of cancer · 2017Pooled it
- Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.Oncotarget · 2016Pooled it
- Pooled it
- Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis.Disease markers · 2015Pooled it
- A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).Targeted oncology · 2016Trial
- LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration.Cell communication and signaling : CCS · 2023Article
- KLF9 inhibits the proliferation, invasion, and migration of renal cell carcinoma through the SDF-1/CXCR4 axis.The Kaohsiung journal of medical sciences · 2023Article
- Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.International journal of molecular sciences · 2023Article
- Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).Bioengineered · 2021Article
- Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma.Clinical and experimental nephrology · 2021Article
- Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Role of CXCL12 in Kidney Diseases: A Friend or Foe?Kidney diseases (Basel, Switzerland) · 2021Review
- PD-1 immunobiology in glomerulonephritis and renal cell carcinoma.BMC nephrology · 2021Review
- CXCL12 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Review
- Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2021Review
- Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019Article
- Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology.Cytokine · 2018Review
- Upregulation of CXCR7 Is Associated with Poor Prognosis of Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Article
- Prognostic significance of CXCR7 in cancer patients: a meta-analysis.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The aim of this study was to evaluate the prognostic impact of the expression of the chemokine SDF-1 and its receptors CXCR4 and CXCR7 in patients with renal cell carcinoma.
methodsThe expression of CXCR4, CXCR7 and SDF-1 in specimens from 97 renal cell carcinoma patients was evaluated by immunohistochemistry on a tissue microarray. These results were correlated with the clinicopathological parameters and survival of the patients.
resultsCXCR4 and CXCR7 were expressed in all patients, whereas SDF-1 was expressed in 61 patients (62.9%). No association was observed between the expression of CXCR4, CXCR7 or SDF-1 and the clinical or pathological data except between SDF-1 expression and Fuhrman's grade (P = 0.015). Patients with high expression of CXCR4, CXCR7 and SDF-1 had shorter overall survival and recurrence-free survival than those with low expression. In a multivariate analysis, the high expression of CXCR4, CXCR7 and SDF-1 correlated with poor overall survival and recurrence-free survival independent of gender, age, AJCC stage, lymph node status, metastasis, histologic variant and Fuhrman's grade.
conclusionsHigh levels of CXCR4, CXCR7 and SDF-1 were associated with poor overall survival and recurrence-free survival in renal cell carcinoma patients. CXCR4, CXCR7 and SDF-1 may serve as useful prognostic markers and therapeutic targets for renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.